At 5.2% CAGR, Middle East & Africa Bioreactors Market is Projected to be Worth US$ 292.40 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa bioreactors market was valued at US$ 194.58 million in 2022 and is expected to reach US$ 292.40 million by 2030, registering a CAGR of 5.2% from 2022 to 2030. Rapid growth of pharmaceutical and biotechnology industry and increasing adoption of single-use bioreactors are among the critical factors attributed to the Middle East & Africa bioreactors market expansion.

In recent years, the pharmaceutical industry has been growing at an unprecedented pace. Big pharmaceutical companies and contract research organizations (CROs) are coming up with new medicines and therapy forms to treat a wide range of indications. The biopharmaceuticals market is increasing. The strong demand for biologics and biosimilars has driven the growth of the industry. Sanofi, AbbVie, and Virax Biolabs are among the biopharma businesses that are discovering a lot of business potential in the Middle East, specifically in Saudi Arabia and the UAE. These nations have become desirable markets for new therapies due to their expanding populations and rising rates of chronic illnesses, including diabetes and cardiovascular disease. By forming strategic alliances with regional organizations, biopharmas can capitalize on incentives provided by governments keen to host innovation hubs, therefore advancing R&D or marketing existing products. For instance, the UAE has created a number of official free economic zones that provide biotech companies that are willing to conduct business internationally with conducive business conditions. These zones, which include the Abu Dhabi Global Market and the Dubai Biotechnology and Research Park, offer a number of benefits, like as tax breaks, 100% foreign ownership, and streamlined administrative procedures. Factors such as increasing biologics approval, growing biosimilar pipeline, and rising investment in research activities are facilitating the growth of the industry.

The increasing approvals in gene and cell therapies are favoring market growth. The approved gene therapies are Glybera-used to treat Lipoprotein Lipase Deficiency and Strimvelis- treating ADA-Severe Combined Immuno Deficiency. Thus, the factors mentioned above are increasing the demand for the large-scale production of various therapeutics, thereby facilitating the growth of the bioreactors market globally.

On the contrary, stringent regulatory framework hurdles the growth of Middle East & Africa bioreactors market.

Based on scale, the Middle East & Africa bioreactors market is categorized into lab-scale production, pilot-scale production, and full-scale production. The pilot-scale production segment held 48.4% share of Middle East & Africa bioreactors market in 2022, amassing US$ 94.15 million. It is projected to garner US$ 139.59 million by 2030 to expand at 5.0% CAGR during 2022-2030.

In terms of application, the Middle East & Africa bioreactors market is segmented into microbial application, cell culture application, and others. The cell culture application segment held 48.6% share of Middle East & Africa bioreactors market in 2022, amassing US$ 94.55 million. It is projected to garner US$ 140.06 million by 2030 to expand at 5.0% CAGR during 2022-2030.

By technology, the Middle East & Africa bioreactors market is bifurcated into fed-batch bioreactors and perfusion bioreactors. The fed-batch bioreactors segment held 62.2% share of Middle East & Africa bioreactors market in 2022, amassing US$ 121.05 million. It is projected to garner US$ 174.21 million by 2030 to expand at 4.7% CAGR during 2022-2030.

Based on end user, the Middle East & Africa bioreactors market is categorized into biopharma manufacturers, research and development organizations, and contract manufacturing organization. The research and development organizations segment held 60.4% share of Middle East & Africa bioreactors market in 2022, amassing US$ 117.55 million. It is projected to garner US$ 185.88 million by 2030 to expand at 5.9% CAGR during 2022-2030.

Based on country, the Middle East & Africa bioreactors market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 31.5% share of Middle East & Africa bioreactors market in 2022. It was assessed at US$ 61.31 million in 2022 and is likely to hit US$ 98.07 million by 2030, exhibiting a CAGR of 6.0% during 2022-2030.

Key players operating in the Middle East & Africa bioreactors market are Applikon Biotechnology BV, General Electric Co, Merck KGaA, Pall Corp, PBS Biotech Inc, Sartorius AG, Solaris Biotechnology SRL, and Thermo Fisher Scientific Inc, among others.

• In December 2022, Merck KGaA announced the acquisition of Erbi Biosystems, a developer of 2 ml micro-bioreactor platform technology. The acquisition has allowed Merck KGaA to incorporate Erbi Biosystems's bioreactor, Breez, into its portfolio and strengthen its therapeutic proteins portfolio. After the acquisition, Merck KGaA aims to increase its Group sales to approximately US$ 26.7 billion ( 25 billion) by 2025.
  
  
• In October 2021, Thermo Fisher Scientific Inc and 3M Separation and Purification Sciences have collaborated on biologics manufacturing. Under the agreement, both companies will incorporate their technologies to produce biologics. The collaboration has enabled their customers to pair the 3M Harvest RC Chromatographic Clarifier, which is a single-stage purification solution, with Thermo Scientific HyPerforma Single-Use Bioreactor Systems. The integration of two technologies will provide great efficiency and scalability in the therapeutic manufacturing process.
  
  
  
  Contact Us
  Phone: +16467917070
  Email Id: sales@businessmarketinsights.com